Ixaltis - Crunchbase Company Profile & Funding

Q: Where is Ixaltis's headquarters?

Ixaltis is located in Toulouse, Midi-Pyrenees, France.

Q: Who invested in Ixaltis?

Ixaltis has 5 investors including IXO Private Equity And Principia SGR.

Q: When was the last funding round for Ixaltis?

Ixaltis closed its last funding round on obfuscated from a Venture - Series Unknown round.

Overview

Ixaltis

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Ixaltis

CB Rank

735665

Ixaltis is a pharmaceutical company that develops therapeutics to treat genitourinary disorders with unsatisfied medical needs.

Founded

obfuscation

Private

Venture - Series Unknown

Toulouse, Midi-Pyrenees, France

11-50

www.ixaltis.com/

Biopharma

Biotechnology

Health Care

Funding Rounds

Venture - Series Unknown

OBF

obfuscation

Key People

Roberto Gradnik: Founder & CEO
Xavier Gamé: Scientific Advisor

Details

Legal Name

IXALTIS SA

Operating Status

Active

Company Type

For Profit

Founders

Christian Chavy, Pascal Rischmann, Philippe Lluel, Roberto Gradnik, Stefano Palea, Xavier Gamé

About the Company

Ixaltis is a pharmaceutical company that develops therapeutics to treat genitourinary disorders with unsatisfied medical needs.

The company was born out of the combined expertise of scientists specialized in urology, pharmaceutical experts and experienced managers: Dr. Philippe Lluel, Christian Chavy, Stefano Palea, Dr. Roberto Gradnik and

Professors Pascal Rischmann and Xavier Gamé. The vision of IXALTIS is to develop treatments for genito-urinary tract diseases with still a high unmet medical need, by identifying drugs which had already reached clinical stage and reexplore these for use in genitourinary tract disorders.

IXALTIS has established a proprietary position covering Litoxetine for use in urogenital and other disorders based on its specific mechanism of action.

Phone Number

+33 (0)4 57 26 00 76

Contact Email

contact@ixaltis.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Litoxetine (IXA-001)

A selective serotonin reuptake inhibitor and mixed serotonin agonist-antagonist developed to treat urinary incontinence by modulating serotonin pathways involved in continence control.

IXA-002

An MAO A-B inhibitor developed for potential treatment of urological diseases, currently in preclinical evaluation following Phase I studies.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Venture Round - Ixaltis	5	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Ixaltis	5	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Ixaltis	5	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Ixaltis	5	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Ixaltis	5	obfuscated obfuscation	—	Venture - Series Unknown

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Venture Round - Ixaltis	5	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Ixaltis	5	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Ixaltis	5	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Ixaltis	5	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Ixaltis	5	obfuscated obfuscation	—	Venture - Series Unknown

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
IXO Private Equity	No	Venture Round - Ixaltis	—
IXO Private Equity	No	Venture Round - Ixaltis	—
IXO Private Equity	No	Venture Round - Ixaltis	—
IXO Private Equity	No	Venture Round - Ixaltis	—
IXO Private Equity	No	Venture Round - Ixaltis	—